Purified exosome product - RION
Alternative Names: 10% PEP; 20% PEP; PEP; PEP Biologic™; PEPTM; Purified Exosome ProductTMLatest Information Update: 28 Feb 2026
At a glance
- Originator Mayo Foundation for Medical Education and Research
- Developer Mayo Foundation for Medical Education and Research; RION
- Class Blood products and substitutes; Exosome therapies
- Mechanism of Action Angiogenesis inducing agents; Exosome replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Osteoarthritis
- Preclinical Alopecia; Joint disorders
- No development reported Myocardial infarction; Urinary incontinence; Wounds
- Discontinued Crohn's disease
Most Recent Events
- 28 Feb 2026 No recent reports of development identified for preclinical development in Urinary-incontinence in USA (Parenteral)
- 22 Oct 2025 Mayo Clinic in collaboration with Rion completes phase I trial in Myocardial infarction in USA (Intracoronary) (NCT04327635)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Myocardial-infarction in USA (Intracoronary, Infusion)